NXL
Nexalin Technology, Inc. (NASDAQ)
Healthcare — Medical Devices
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Price History
Fundamentals
| Market Cap | $8.19M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.23 |
| EPS (TTM) | $-0.46 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -63.60% |
| ROE | -319.69% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $2.00 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 34.5 |
| Beta | 3.84 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.00 |
| 52-Week Low | $0.31 |
| 50-Day Avg | $0.41 |
| 200-Day Avg | $0.70 |
| Avg Volume | 871.9K |
| Volume | 329.0K |
Performance Analysis
NEUTRALNXL presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:23 UTC
Back to Screener Export Report